I løbet af en periode på 2 år blev risikoen for forværring af invaliditeten mindsket med 42% i forhold til placebo.
Tysabri was also more effective than placebo on the disabling effects of MS: over two years, the risk of disability getting worse was reduced by 42% in comparison with placebo.